Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 4:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 505–528 of 2,274 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Melanoma Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

fPAM for the in Vivo Depth Measurement of Pigmented Lesions and Melanoma Depth

NCT02613325
View directory record Official record
Conditions
Pigmented Skin Lesion, Melanoma
Interventions
Functional photoacoustic microscopy, Standard of care surgical excision, Single cell photoacoustic microscopy
Device · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 14, 2018 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

NCT02857374
View directory record Official record
Conditions
Stage IB Skin Melanoma, Stage IIA Skin Melanoma, Stage IIB Skin Melanoma, Stage IIC Skin Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma, Stage IIIC Skin Melanoma
Interventions
Diagnostic Microscopy, Fluorescein Sodium Injection, Laboratory Biomarker Analysis, Sentinel Lymph Node Biopsy
Procedure · Drug · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2022 · Synced Oct 23, 2026, 4:41 PM EDT
Active, not recruiting Phase 3 Interventional

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Digestive System Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
Interventions
Computed Tomography, Fractionated Stereotactic Radiation Therapy, Magnetic Resonance Imaging, Stereotactic Radiosurgery
Procedure · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
262
States / cities
Tucson, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 189 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Phase 2 Interventional

LMB-2 Immunotoxin and Vaccine Therapy in Treating Patients With Metastatic Melanoma That Cannot Be Removed By Surgery

NCT00295958
View directory record Official record
Conditions
Melanoma (Skin), Non-melanomatous Skin Cancer
Interventions
LMB-2 immunotoxin, MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant
Biological
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 14, 2012 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

NCT01831726
View directory record Official record
Conditions
Tumor Pathway Activations Inhibited by Dovitinib
Interventions
Dovitinib (TKI258)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
49
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Pismo Beach, California + 43 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2017 · Synced Oct 23, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Carboplatin, Paclitaxel, and Temozolomide for Patients With Metastatic Melanoma

NCT01009515
View directory record Official record
Conditions
Melanoma
Interventions
Paclitaxel, carboplatin, temozolomide
Drug
Lead sponsor
New Mexico Cancer Research Alliance
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
3
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Phase 3 Interventional Results available

A Study Comparing Trametinib and Dabrafenib Combination Therapy to Dabrafenib Monotherapy in Subjects With BRAF-mutant Melanoma

NCT01584648
View directory record Official record
Conditions
Melanoma
Interventions
Dabrafenib, Trametinib, Trametinib placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
423 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
19
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 23, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma

NCT01468818
View directory record Official record
Conditions
Metastatic Melanoma, Skin Cancer
Interventions
Cyclophosphamide, Fludarabine, Young Tumor Infiltrating Lymphocytes (TIL)
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 23, 2026, 4:41 PM EDT
Recruiting Phase 2Phase 3 Interventional

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

NCT06581406
View directory record Official record
Conditions
Metastatic Uveal Melanoma
Interventions
RP2, Ipilimumab, Nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
Not listed
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
29
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 23 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 23, 2026, 4:41 PM EDT
Terminated Phase 1 Interventional

Interleukin-7 in Treating Patients With Metastatic Melanoma or Locally Advanced or Metastatic Kidney Cancer

NCT00492440
View directory record Official record
Conditions
Kidney Cancer, Melanoma (Skin)
Interventions
recombinant interleukin-7, gene expression analysis, polymerase chain reaction, protein expression analysis, flow cytometry, immunoenzyme technique, immunologic technique, laboratory biomarker analysis, pharmacological study
Biological · Genetic · Other
Lead sponsor
Cytheris SA
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2012 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Fibrin Melanoma Axillary Node Study in Patients With Melanoma

NCT00504582
View directory record Official record
Conditions
Melanoma
Interventions
Fibrin Sealant
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2023 · Synced Oct 23, 2026, 4:41 PM EDT
Terminated No phase listed Observational

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics

NCT05819827
View directory record Official record
Conditions
Bladder Cancer, Prostate Cancer, Testicular Cancer, Bladder Carcinoma, Genitourinary System Carcinoma, Malignant Testicular Neoplasm, Melanoma, Prostate Carcinoma, Sarcoma
Interventions
Blood and Tissue
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
20 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Not applicable Interventional Results available

Wearable Device Intervention to Improve Sun Behaviors in Melanoma Survivors

NCT03927742
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Shade + app with messaging, Shape + app without messaging
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 75 Years
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 13, 2024 · Synced Oct 23, 2026, 4:41 PM EDT
Not listed Phase 1 Interventional

Abraxane and Temodar Plus Genasense in Advanced Melanoma

NCT00409383
View directory record Official record
Conditions
Melanoma
Interventions
Genasense® (oblimersen), Abraxane® (paclitaxel protein-bound particles for injectable suspension), Temodar® (temozolomide)
Drug
Lead sponsor
Genta Incorporated
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Neoadjuvant Temozolomide in Melanoma Patients With Palpable Stage III or IV Disease Undergoing Complete Surgical Resection

NCT00588341
View directory record Official record
Conditions
Melanoma, Skin Cancer, Cancer
Interventions
Temozolomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 1, 2016 · Synced Oct 23, 2026, 4:41 PM EDT
Not listed No phase listed Observational

Evaluating the Effects of Cannabis Use and Circulating Cannabinoids on Tumor Infiltrating Lymphocytes in Malignant Melanoma

NCT05520294
View directory record Official record
Conditions
Melanoma
Interventions
High-performance liquid chromatography-tandem mass spectrometry assays
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 100 Years
Enrollment
90 participants
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 23, 2026, 4:41 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma

NCT04695977
View directory record Official record
Conditions
Melanoma, Advanced Melanoma, Metastatic Melanoma, Unresectable Melanoma
Interventions
CMP-001, Nivolumab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • La Jolla, California + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Sunscreen Based on Bioadhesive Nanoparticles

NCT02668536
View directory record Official record
Conditions
Melanoma, UV Ray Skin Damage
Interventions
Standard Sunscreen, BNP
Drug · Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

A Phase 1B Clinical Trial of Trametinib Plus Digoxin in Patients With Unresectable or Metastatic BRAF Wild-type Melanoma

NCT02138292
View directory record Official record
Conditions
Melanoma
Interventions
Trametinib (2mg)/Digoxin (.25mg)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2018 · Synced Oct 23, 2026, 4:41 PM EDT
Completed No phase listed Observational

Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles

NCT00005781
View directory record Official record
Conditions
Dermatitis, Nevus, Psoriasis
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 4:41 PM EDT
Terminated Phase 2 Interventional Results available

STA-9090(Ganetespib) in Patients With Unresectable Stage III or Stage IV Melanoma

NCT01551693
View directory record Official record
Conditions
Melanoma
Interventions
STA-9090
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Oct 23, 2026, 4:41 PM EDT
Not listed Phase 3 Interventional

Interleukin-2 With or Without Histamine Dihydrochloride in Treating Patients With Stage IV Melanoma Metastatic to the Liver

NCT00039234
View directory record Official record
Conditions
Melanoma (Skin), Metastatic Cancer
Interventions
aldesleukin, histamine dihydrochloride
Biological · Drug
Lead sponsor
Maxim Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
11
States / cities
Santa Monica, California • Aurora, Colorado • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Not applicable Interventional

Minimally Invasive Groin Dissection for Melanoma

NCT01500304
View directory record Official record
Conditions
Melanoma
Interventions
Minimally invasive inguinal lymph node dissection
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
11
States / cities
Scottsdale, Arizona • Santa Monica, California • Jacksonville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2018 · Synced Oct 23, 2026, 4:41 PM EDT
Completed Phase 1 Interventional

Immune Responses to Autologous Langerhans-type Dendritic Cells Electroporated With mRNA Encoding a Tumor-associated Antigen in Patients With Malignancy: A Single-arm Phase I Trial in Melanoma

NCT01456104
View directory record Official record
Conditions
Melanoma
Interventions
Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
Not listed
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2023 · Synced Oct 23, 2026, 4:41 PM EDT